| Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation. | colorectal, |
| loss of the wild-type KRAS allele is a secondary mutation in all T-ALL cells; wild-type KRAS acts as a tumor suppressor in the T-cell lineage in mice | None |
| demonstrate the tumor suppressor function of WT Kras in oncogenic Kras-induced leukemogenesis and elucidate its underlying cellular and signaling mechanisms. | None |
| Results show that Notch signalling exerts opposing effects in oncogenic Kras-induced MPN; it functions as a potent oncogene in leukaemia cells per se (Kong et al , 2019), but acts as a tumour suppressor gene in non-haematopoietic cells. | None |
| [The correlation between expression of oncogene protein products p53, p21, p185 and cell differentiation and prognosis in rhabdomyosarcoma]. | sarcoma, |
| Genetic epidemiology of mutated K-ras proto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas. | colorectal, |
| K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. | lung, |
| [Prognostic value of the presence of the mutation of the codons 12, 13 and 61 in K-ras oncogene in colorectal cancer]. | colorectal, |
| Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. | colorectal, |
| Detection of codon 12 mutation in the K-ras oncogene in pancreatic tumors. | pancreatic, |
| Alterations of protein kinase C, 8-hydroxydeoxyguanosine, and K-ras oncogene in rat lungs exposed to passive smoking. | lung, |
| Cytogenetic damage and ras p21 oncoprotein levels from patients with chronic obstructive pulmonary disease (COPD), untreated lung cancer and healthy controls. | lung, |
| [Analysis of prevalence of point mutations in codon 12 of oncogene K-ras from non-cancerous samples of cervical cytology positive for type 16 or 18 PVH]. | cervical, |
| [Detection of K-ras oncogene mutations in human lung cancer by PCR-SSCP-DNA direct sequencing]. | lung, |
| Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma. | thyroid, |
| The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. | colorectal, |
| Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. | colorectal, |
| K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. | pancreatic, |
| K-ras oncogene mutation in cancer and precancerous lesions of the gallbladder. | bladder, |
| [Expression of ras oncogene p21 product and proliferating cell nuclear antigen in liver cirrhosis and the correlation with liver cell dysplasia]. | liver, |